Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RayVa Phase 2a in Raynaud's Phenomenon Secondary to SSc
NCT02228850Phase 2Completed
- Sponsor
- Apricus Biosciences, Inc.
- Start
- Nov 2014
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Alprox in Raynaud phenomenon (3 cohorts), sponsored by Apricus Biosciences, Inc. Primary endpoints: Digital perfusion by laser Doppler capillary velocimetry, Digital temperature recovery with thermography and 1 more. Started Nov 2014; status: completed.
02
Drugs
Alprox
03
Conditions
Raynaud phenomenon
Beyond the preview
Go deeper on NCT02228850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02228850.